ArticlePloS one2025
Space-time analysis of head and neck cancer in Asia and its 34 countries and territories (1990-2021): Implications from the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unraveling the molecular landscape: an overview on gene expression, epigenetic alterations, and therapeutic challenges in head and neck squamous cell carcinoma.Molecular genetics and genomics : MGG · 2026Review
- Efficacy of Pembrolizumab as a Second- or Third-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter Retrospective Study in Vietnamese Patients.Clinical Medicine Insights. Oncology · 2026Article
- Robotic infraclavicular approach for minimally invasive neck dissection: an evaluation of safety, oncologic efficacy, and learning curve dynamics in head and neck cancer surgery.Frontiers in oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsia bears a disproportionate burden of head and neck cancer (HNC). This study aimed to analyze its spatial distribution and temporal trends in Asia from 1990 to 2021, projecting trends to 2030.
methodsWe performed a secondary analysis of data from the Global Burden of Disease Study (GBD) 2021, examining disability-adjusted life years (DALYs) for HNC and its five major subtypes: nasopharyngeal cancer (NPC), thyroid cancer (TC), laryngeal cancer (LC), lip and oral cavity cancer (LOC), and other pharyngeal cancer (OPC), across five Asian subregions and 34 countries/territories from 1990 to 2021. Temporal trends were evaluated using Joinpoint regression, and projections to 2030 were generated through Bayesian Age-Period-Cohort model.
resultsFrom 1990 to 2021, DALYs for HNC increased in five subregions. In contrast, age-standardized DALY rates (ASDR) declined across all subregions except South Asia, with East Asia experiencing the most rapid decrease. In 2021, South Asia recorded the highest DALYs (6,412,639) and ASDR (405.82 per 100,000) for HNC. LOC was the main HNC type in most regions (32.41% - 46.23%), except East Asia, where NPC was most common (38.96%). South Asia also exhibited the highest ASDRs for LC (67.29), LOC (182.29), and OPC (93.00) per 100,000, while Southeast Asia demonstrated the highest ASDRs for NPC (50.77) and TC (18.22) per 100,000. Significant disparities in ASDR trends for HNC subtypes were observed across Asia. By 2030, South Asia is projected to maintain the highest ASDRs for HNC (394.59), LC (62.98), LOC (185.31), and OPC (95.50). East and Southeast Asia are expected to show comparable ASDRs for NPC (approximately 50.00), with Southeast Asia leading in TC ASDR (23.90).
conclusionsHNC remains a significant public health challenge in Asia, with substantial heterogeneity in its subtypes across the five subregions. Implementing targeted, region-specific strategies is crucial to mitigating the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.